CDH1 and colorectal carcinoma: In colorectal carcinoma, previous study revealed that reduction of E-cadherin is seen approximately in 38–46% of the patients accompanied by significant poor survival, which is consistent in part with our present study (Mohri, 1997; Ghadimi et al, 1999; Karatzas et al, 1999; Ikeguchi et al, 2000; Aoki et al, 2003).